Navigation Links
Antibody-guided drug shows encouraging activity in metastatic breast cancer
Date:12/12/2009

SAN ANTONIO, TXA new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

The findings will be presented at the 32nd annual CTRC-AACR San Antonio Breast Cancer Symposium on Saturday, Dec. 12 (Abstract 710, Henry B. Gonzalez Convention Center, Exhibit Hall B, 7-9 a.m. CT).

Ian Krop, MD, PhD, principal investigator of the study, will report that the hybrid agent, called T-DM1, shrank tumors by 30 percent or more in 40 percent of women with confirmed HER2-positive cancers. Another 13 percent had stable disease for at least six months, for a total clinical benefit rate of approximately 53 percent. The median time before the disease progressed was 7.3 months, including both responders and non-responders. Patients received T-DM1 as long as it was effective and well-tolerated. A total of 110 women were enrolled in the study.

T-DM1 is comprised of the cell-killing drug DM1 and is chemically linked to the monoclonal antibody trastuzumab, which selectively binds to the HER2 growth signal receptor, which is highly overexpressed in HER2-positive breast tumors. Approximately 20 percent of breast cancers are HER2-postive.

Trastuzumab, developed by Genentech and sold under the name Herceptin, has markedly improved the treatment of HER2-positive cancer, but resistance to trastuzumab is a significant problem.

"The antibody binds to the HER2 protein on tumor cells and delivers the drug (DM1) selectively to them but not to normal cells," Krop explained. "This allows us to deliver high doses of the chemotherapy directly to tumor cells. And at the same time, the antibody continues to block the HER2 growth signals."

Krop said that one of the unique features of the study is that i
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. New research shows how chronic stress worsens neurodegenerative disease course
3. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
4. Circulating fats kill transplanted pancreas cells, study shows
5. New Heart Pump Shows Promise in Trial
6. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
7. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
10. Avocados may help prevent oral cancer, OSU study shows
11. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 Hosted by ... Cares free dental clinic provided more than $1.6 million ... May 18-19 in San Jose. , The California ... the clinic to provide free dental services and oral ... This is the third clinic held by CDA and ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Anyone ... is something about feet that fungi seem to like. ... the fungal groups that live on your skin -- ... It,s no secret that the human body is ... fungi, both outside and inside. And it,s mainly a ...
(Date:5/22/2013)... 2013 Successful Therapy for Parents ... Psychotherapy in the Silver Lake community of Los ... as progression to existing Parents and Couples counseling ... parenting therapy has always been suggested, but now ... now specializes in all aspects of relationships ...
(Date:5/22/2013)... 22, 2013 According to a May 14, ... More Options for Breast Cancer Surgery,” modern medical technology has ... approach this disease in a whole new light. Since the ... now face breast cancer and mastectomies with greater ... “Before the introduction of plastic surgery to oncology, women had ...
(Date:5/22/2013)... Researchers in genomic health disparities from the University of ... School of Medicine have teamed up to hold the ... Health Disparities in Genomic Medicine." The theme of ... business and government to reduce these disparities. , Despite ... States, individuals within underserved groups continue to be more ...
Breaking Medicine News(10 mins):Health News:Two-day San Jose Dental Clinic Provides More Than $1.6 Million in Care 2Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2
... health system of southern Australian hospitals has been graded at ... surgery admissions //and waiting times. ,This rating has ... recorded the second highest number of beds per capita in ... for every 1000 in population. ,Health Minister Tony ...
... New South Wales in Australia have developed a "super ... diabetes//, heart disease, arthritis and cancer. The drug, Dz13, ... aging as well, the researchers claimed. ,Also diseases like ... in a paper published in the latest issue of ...
... Pharma today said it has recieved a tentative New ... product used for treating HIV-1 infection//. ... drug product containing Lamivudine, Zidovudine, Nevirapine tablets used in ... Bombay Stock Exchange., ,The three drugs would now ...
... have discovered a method to cease the blood supply to ... cancer//. This, if proved conclusively, will infuse a new lease ... a protein, discovered while conducting a research on fruits, is ... them naturally. , ,The researchers said “By blocking the ...
... members and villagers, a woman who lost her husband to AIDS ... Bihar home. ,Premila Devi, 40, from Tilaei village in ... just a few months after her husband Sunil Mahto died of ... members as well as villagers treated her after her husband's death," ...
... determination test kits to counter online threats to its skewed ... Home DNA gender testing kit' for $275 promising results within ... unborn girls in Punjab, Haryana and Delhi. ,"We ... Health Minister Ramesh Chander Dogra told a news channel Sunday. ...
Cached Medicine News:Health News:South Australian health System In The Bottom Of Rankings 2
(Date:5/22/2013)... 2013  Grifols, ein globales Unternehmen der ... , Spanien, präsentierte die Ergebnisse einer ... von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des ... ein Niveau anhebt, das innerhalb des für ... ist eine lebensbedrohliche, genetische Erkrankung, bei der ...
(Date:5/22/2013)... Israel , May 22, 2013 /PRNewswire/ ... leading developer and provider of microRNA-based molecular diagnostics, announces ... and Chief Executive Officer of Rosetta Genomics, will deliver ... taking place from June 3-6, 2013 in New York ... June 4 th at 2:00 p.m. Eastern time. ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... June 21 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, presented clinical data and analysis from ... patients with type 2 diabetes mellitus at ENDO 2010 today. ... of increased total GLP-1 in both LX4211 treatment arms relative ...
... 21 Reportlinker.com announces that a new market research report is available ... Global Coronary ... , , ... , , ...
Cached Medicine Technology:Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 2Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 3Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 4Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 12Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 13Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 14Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 15Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 16
... Quality EEG recording is assured even ... Neurofax has high performance, high sensitivity ... ECG rejection filter, shielded electrodes and a ... connection. Neurofax is a complete and ...
... MagPro is the high performance magnetic stimulator ... in medical research. , ,MagPro is able to ... precise studies of the field/nerve interface can be ... biphasic waveform and coil-current direction. , , , ...
... is a new top-line range of digital ... Atrial Fibrillation (AF). Because the T-series combines ... the treatment of AF is taken one ... the heart rhythm is monitored continuously and ...
... MAX Cooling Power, Deeper Lesions ... arrhythmias, including atrial flutter, Freezor MAX is ... catheter with an 8mm ablation tip was ... is connected to the same cryoconsole as ...
Medicine Products: